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Background: Supra-physiological concentrations of ascorbate, vitamin C, in blood, greater than 1 mM,
achieved through intravenous administration (IV), are being tested in clinical trials to treat human dis-
ease, e.g. cancer. These trials need information on the high levels of ascorbate achieved in blood upon IV
administration of pharmacological ascorbate so appropriate clinical decisions can be made.
Methods: Here we demonstrate that in the complex matrix of human blood plasma supra-physiological
levels of ascorbate can be quantiﬁed by direct UV spectroscopy with use of a microvolume UV–vis
spectrophotometer.
Results: Direct quantitation of ascorbate in plasma in the range of 2.9 mM, lower limit of detection, up to
at least 35 mM can be achieved without any sample processing, other than centrifugation.
Conclusions: This approach is rapid, economical, and can be used to quantify supraphysiological blood
levels of ascorbate associated with the use of IV administration of pharmacological ascorbate to treat
disease.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the discovery of vitamin C, ascorbic acid/ascorbate
(AscH2/AscH) [1], many methods for its analysis in foods, biolo-
gical ﬂuids, and tissues have been developed. In human blood
plasma concentrations of AscH in the range of E40–80 mM are
considered normal and healthy [2]. The highest concentration of
AscH that can be achieved in blood plasma via oral administra-
tion is on the order of 200 mM or so [3]. However, supra-physio-
logical concentrations in blood, E10,000 to 30,000 mM or more,
achieved through intravenous administration (IV), are being tested
in clinical trials to treat human disease, e.g. cancer [4–9]. These
types of trials need information on the high levels of AscH
achieved in blood upon IV administration of pharmacological
AscH so appropriate clinical decisions can be made. Thus, rapid
and economical assays for these high levels of AscH in blood
plasma/serum are needed.B.V. This is an open access article u
logy Radiation, Oncology and
a, Iowa City, IA 52242-1181,
Witmer),
wa.edu (B.A. Wagner),
(J.J. Cullen),A wide variety of assays for the levels of AscH in cultured
cells, biological ﬂuids, and tissues have been developed: direct
measurement via HPLC [10–12], colorimetric methods [13], ﬂuor-
escence of products formed upon reaction with dehydroascorbic
acid [14,15], use of the chemistry in a ﬁngerstick blood glucose
monitor [16], and by electron paramagnetic spectroscopy [17].
Ascorbic acid is a diprotic acid with pKa1¼4.0 at an ionic
strength of 150 mM and pKa2¼11.5 [18–20]. Thus, at near-neutral
pH, the dominant form will be the AscH monoanion. Ascorbic
acid and the AscH monoanion have distinctly different ultraviolet
(UV) spectra. The diprotic acid, AscH2, has a maximum molar ab-
sorptivity at 243 nm, ε243¼9650 M1 cm1 [21]. The AscH
monoanion has an absorption maximum at 265 nm. Many values
for its molar absorptivity have been reported, with ε265 ranging
from 7500 to 20,400 M1 cm1 [20,21]. A careful study found
ε265¼14,5607450 M1 cm1 and ε251¼82507150 M1 cm1
at the isobestic point (250.7 nm) for the diacid and the
monoanion [21]. When unwanted oxidation is avoided,
ε265¼14,500 M1 cm1 is the maximum UV absorbance of AscH
[22]. These values for the molar absorptivity allow quantiﬁcation
of AscH in aqueous buffers when [AscH] is greater than about
5 μM using a typical UV spectrophotometer (1.00 cm cuvette).
Here we propose that in the complex matrix of human blood
plasma supra-physiological [AscH] of 3–30 mM, achieved by IV
administration [4], can be quantiﬁed by direct UV spectroscopy.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quantitation in plasma without any sample processing (i.e. no
chemistries and no dilutions), other than centrifugation of the
whole blood to deplete platelets and remove red blood cells.2. Materials and methods
2.1. Plasma samples
Blood plasma samples were from subjects of clinical trials
being conducted at The University of Iowa that are investigating
the use of pharmacological AscH as an adjuvant in the treatment
of cancer. These trials were approved by The University of Iowa IRB
and are listed on https://clinicaltrials.gov [4–6]. Whole blood was
collected using BD Vacutainer
s
green top blood collection tube,
4 mL, NaHeparin 75 USP units. Samples were centrifuged at 2000g
for 15 min; RBC-free, platelet-depleted plasma was collected for
analysis. The plasma was divided into aliquots (650 μL) and ana-
lyzed for AscH immediately or stored at 80 °C for later analysis.
We found that AscH in plasma was quite stable for long periods
of time at 80 °C, consistent with detailed studies on the stability
of AscH in plasma [23–25].
2.2. UV/Vis spectroscopy
2.2.1. Standard curve
A 0.100 M [AscH] standard solution (10.0 mL) was prepared in
a phosphate buffer, PBS pH¼7.0 with [phosphate]¼100 mM; all
buffers were treated with chelating resin to remove adventitious
catalytic metals [22]. The exact concentration of the stock solution
was veriﬁed by absorbance at 265 nm, ε265¼14,500 M1 cm1
[22]. Absorbance measurements were accomplished using an Im-
plen Nanophotometer P-330 with a 250 dilution lid, path
length¼4.00103 cm, i.e. 40 μm. Nine separate dilutions using
the 0.100 M [AscH] stock solution and PBS pH¼7.0 buffer were
made. The concentrations of these standard solutions (250 μL total
volume each) were: 35.0, 30.0, 25.0, 20.0, 15.0, 10.0, 5.0, 2.5, 1.3,
and 0.0 mM.
All standard curve samples were examined in triplicate. The
standard curve was prepared using the median obtained for each
standard [26].
2.2.2. Standard addition
Using standard solutions of AscH , a standard addition was
made to plasma samples obtained from four different subjects.
Absorbance measurements at 265 nmwere accomplished using an
Implen Nanophotometer P-330 with a 250 dilution lid (path
length¼4.00103 cm¼40 μm). Nine separate standard addi-
tions using the 0.100 M [AscH] stock solution in plasma samples
were made. The concentrations of these standard additions
(250 μL total volume each) were: 35.0, 30.0, 25.0, 20.0, 15.0, 10.0,
5.0, 2.5, 1.3, and 0.0 mM. Care must be taken to thoroughly clean
the lid and cuvette surfaces as AscH quickly crystallizes out of
solution leading to incorrect readings of absorbance.
All experimental samples were examined in triplicate. To de-
termine the absorbance due to AscH at 265 nm any absorbance
from the 0.0 mM sample was subtracted out. The standard addi-
tion curve was prepared using the median obtained for each
standard [26].
2.2.3. Reduction of dehydroascorbic acid to ascorbate
We conﬁrmed that plasma samples had undetectable amounts
of dehydroascorbic acid (DHA), the two-electron oxidation product
of AscH , by addition of dithiothreitol (DTT). A stock solution of
DHA was made in 10 mM phosphate buffer, pH 6.5, by adding10 mg of DHA to 1.00 mL buffer; a working solution was made by
diluting 1.5 mL of stock solution into 1.00 mL of buffer yielding
86 mM DHA. A stock DTT solution was prepared with 50 mg of DTT
solubilized into 1.00 mL of 10 mM phosphate buffer, pH 6.5. A blank
with deionized water was collected using a 1.00 cm path length
cuvette in an Implen Nanophotometer. The working solution of
DHA was added and a baseline spectrum, 250–900 nm, was ob-
tained. As soon as possible after adding and mixing 4 mL of DTT
stock another spectrum was obtained. Then additional spectra
were captured at 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240, and
300 s after mixing with DTT.
2.2.4. Statistical approaches
All margins of error displayed in graphs and provided in the
text were determined using Igor 5.03 software (WaveMetrics, Inc.,
Lake Oswego, OR) and represent one standard deviation. The
lower limit of detection for [AscH] in neutral buffer was found to
be 2.9 mM as determined using the calibration plot method [27].
All uncertainties presented are standard deviations unless noted
otherwise. Precision was addressed by repeated measurements of
absorbance of the plasma at 265 nm from a single subject using an
Implen Nanophotometer P-330 with a 250 dilution lid. Absor-
bance of both the pre-infusion and post-infusion plasma was de-
termined ten or more times on 5 different days.3. Results and discussion
3.1. UV/Vis spectra of known concentrations of ascorbate in pH
neutral buffer
To determine the response of the microvolume UV/Vis spec-
trometer to AscH in typical near-neutral buffer, aliquots of an
AscH standard solution, prepared gravimetrically, were added to
Chelex
s
-treated phosphate buffer (100 mM, pH 7.0) to achieve a
series of known concentrations, 0–35 mM. Using a microvolume
UV/Vis spectrometer in conjunction with a 250 dilution lid (path
length¼4.00103 cm¼40 μm), spectra were captured for the
various [AscH], Fig. 1. Using ε265¼14,500 M1 cm1 [22], a plot
of the measured concentrations of AscH (ordinate) vs. the con-
centration of the gravimetrically prepared standard (abscissa)
showed the expected linear response, slope¼0.91, R2¼0.998.
Concentrations from 2.9 mM, lower limit of detection, up to at
least 35 mM can be determined directly with no dilution [27]. A
35 mM solution of AscH in a 1.00 cm cuvette would have a the-
oretical absorbance of 508 at 265 nm. These results indicate that
use of a microvolume UV/Vis spectrometer has the potential for
use to assess quickly pharmacological [AscH] in plasma.
3.2. Ascorbate concentrations in blood plasma after standard addi-
tions of ascorbate
In order to examine the potential for the direct detection of
AscH in plasma using a microvolume UV/Vis spectrometer,
standard additions of AscH were made to blood plasma samples
from four different subjects to achieve known concentrations
ranging from 0.0 to 35.0 mM. As expected, with no addition of
AscH , there is an absorbance in the same region as the AscH
absorption due to the protein in the plasma. Addition of known
amounts of AscH to the samples of plasma resulted in increasing
absorbance at 265 nm, Fig. 2. The concentration of AscH from the
absorbance measurement of the microvolume UV/Vis spectro-
meter (ordinate) was calculated by subtracting the absorbance of
the baseline from each standard addition of AscH and applying
the path length, 4.00103 cm, and molar extinction coefﬁcient
ε265¼14,500 M1 cm1 [22]. An excellent linear correlation was
Fig. 1. UV/Vis spectra of known concentrations of ascorbate in pH neutral buffer. Aliquots of an AscH standard solution, prepared gravimetrically, were added to Chelexed
phosphate buffer (100 mM, pH 7.0) to achieve a series of known concentrations. An Implen Nanophotometer P-330 with 250 dilution lid (path length¼4.00103 cm)
was used to gather spectra. (A) A plot of one set of spectra of various [AscH] (0.0, 1.3, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, and 35.0 mM). (B) The measured [AscH] (ordinate)
were determined using ε265¼14,500 M1 cm1 [21,22] are plotted against the concentration of the gravimetrically prepared standard (abscissa); slope¼0.9170.02,
R2¼0.998. The blank was buffer only.
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levels of AscH in plasma, 2.9 mM lower limit of detection, up to
at least 35 mM can be determined directly with no sample
processing.
To estimate the effective molar extinction coefﬁcient for AscH
in plasma at 265 nm a plot of the absorbance obtained directly
from the Implen Nanophotometer P-330 with a 250 dilution lid
vs. the known standard was made, Fig. 2C. The slope of this line
will yield the apparent molar extinction coefﬁcient in the matrix of
plasma. This line has a slope¼0.05370.002 mM1; in standard
units for molar extinction coefﬁcients, this slope yields
ε265¼13,0007500 M1 cm1.
3.3. The direct assay agrees well with results from a ﬂuorescence
plate reader assay
In order to determine how the results of the direct assay for
AscH in plasma using a microvolume UV–vis spectrophotometer
agree with another assay, we analyzed a large set of plasma
samples (n¼179) from subjects that were participating in clinical
trials of pharmacological AscH as an adjuvant in cancer treat-
ment [4–6]. The plasma samples from the trials were analyzed
using a kinetic-based assay [4,15]. We found remarkable agree-
ment between the plasma concentrations determined for AscH
by these two very different assays, as manifest in the slope of 1.00
when plotting the [AscH] for each assay, Fig. 3.
Many assays for [AscH] in plasma precipitate the protein
[12,15]. This results in a decease in the effective volume of the
plasma sample; as a result the [AscH] in the plasma will be
overestimated. The partial speciﬁc volume of protein is approxi-
mately 0.73 cm3 g1 [28]. Plasma is 7.5% protein, or 75 g L1; thus,
(75 g/1000 mL) (0.73 cm3/g)100%¼5.5% of the volume of
plasma is protein. If this protein is removed, then the [AscH] will
be concentrated by E5.8% (100/94.5). In the direct assay using a
microvolume UV/Vis spectrometer the protein is not removed
while in the kinetic ﬂuorescence assay it is removed. If the cor-
rection for protein volume is not made, then the slope through the
origin in Fig. 3 is 0.95, exactly as predicted. This demonstrates the
importance of considering the volume of protein, if removed in
any type of quantitative assay.3.4. Ascorbate concentrations determined in plasma using an aver-
age blank
In Fig. 3 the blank for each sample was the plasma from a blood
sample drawn just before infusion of pharmacological AscH .
However, such a sample may not always be available nor needed
to minimize discomfort and risk. To determine if an average blank
for the absorbance at 265 nm can be used, 170 samples were
analyzed for the concentration of AscH . A comparison was made
between the results using the average absorbance at 265 nm of
all 170 samples as a blank compared to using the pre-infusion
blood sample as a blank for each subject, Fig. 4. For the values of
the abscissa the blank was the corresponding plasma of each
subject taken prior to infusion of pharmacological AscH . For
the ordinate the blank was the average of the absorbance at
265 nm (0.2370.04, path length¼4.00103 cm) of the pre-in-
fusion samples for all 170 subjects. A slope of 0.98 demonstrates
that an average blank can be used to estimate the supra-physio-
logical [AscH]. Thus, a pre-infusion sample of plasma is not
necessary.
To estimate the precision of the assay, the absorbance at
265 nm from a single sample of plasma was determined multiple
times (nZ10) on ﬁve different days. The absorbance values at
265 nm for the pre-infusion samples were, in order of day 1-day 5,
mean, medium, (standard deviation): 0.16, 0.15, (0.01); 0.21, 0.20,
(0,03); 0.22, 0.22, (0.02); 0.23, 0.23, (0.02); and 0.19, 0.19, (0.01);
respectfully. The absorbance at 265 nm for the post-infusion
samples were, in order of day 1 to day 5, mean, medium, (standard
deviation): 1.01, 0.98, (0.08); 1.11, 1.07, (0.12); 1.03, 1.02, (0.05);
1.06, 1.03, (0.11); and 1.00, 0.99, (0.04); respectfully. The coefﬁcient
of variation for each day was determined and the average for the
pre-infusion was found to be 9.4% and for the post-infusion, 7.8%.
Using these absorbance data, path length¼4.00103 cm, and
ε265¼13,000 M1 cm1, the estimated concentration of AscH
from each the ﬁve days would be: 16.0, 16.7, 15.4, 15.4, 15.4 mM;
median¼15.4 mM. If one uses the average absorbance of
0.2370.04 for the blank, the estimated concentration of AscH
from each the ﬁve days would be: 14.4, 16.2, 15.2, 15.4, 14.6;
median¼15.2 mM, excellent agreement between the two
approaches.
Fig. 2. Spectrophotometric determination of ascorbate concentrations in blood plasma after standard additions of ascorbate. Standard additions of AscH were made to
blood plasma samples from four different subjects to achieve known concentrations of 0.0, 1.3, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, and 35.0 mM. Absorbance was determined
using an Implen Nanophotometer P-330 with 250 dilution lid, i.e. path length¼4.00103 cm. (A) One set of example spectra obtained after the standard additions to the
plasma of one subject. (B) The measured AscH concentration (ordinate) was calculated by taking the difference between absorbance of the baseline, 0.0 mM AscH , from
each standard addition of AscH . The difference was then used to determine the measured [AscH] using ε265¼14,500 M1 cm1 [21]. From these data a plot was generated
using the median values obtained from the measured [AscH] and plotted against the known gravimetric standard; slope¼0.9870.02, R2¼0.996. (C) A plot of the ab-
sorbance obtained directly from the Implen Nanophotometer P-330 with a 250 dilution lid is plotted against the known gravimetric standard; slope¼0.05370.002 mM1
2501 cm1. Converting this to standard units for the molar extinction coefﬁcient and accounting for the dilution, ε265 nm¼13,0007500 M1 cm1. This is the apparent
molar extinction coefﬁcient for AscH in plasma. All measurements were done in triplicate.
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the squares of the coefﬁcients of variation) yielding a coefﬁcient of
variation of about 13%, if a pre-infusion sample is available as a
blank. If the average blank is used, then the estimated coefﬁcient
of variation would be about 20%, the largest contribution coming
from the biological variation in the absorbance of the plasma at
265 nm. Normal levels of AscH in plasma range from E40–
80 μM; these levels of AscH in plasma would contribute 0.002–
0.004 absorbance units to the blank (4.00103 cm path length),
i.e. at the noise level. Thus, if an average blank is used, the varia-
tion observed is, as expected, from the biological variation in the
protein content of plasma [29].3.5. The reduction of dehydroascorbic acid to ascorbate by dithio-
threitol is rapid
Ascorbate can readily undergo oxidation, resulting in formation
of DHA. It has long been known that thiols such as glutathione will
reduce DHA back to AscH [30]. To determine if a signiﬁcant
amount of the AscH had oxidized to DHA we used dithiothreitol
(DTT) as a reducing agent [31]. When an excess of DTT was added
to DHA in near-neutral buffer, the reduction to AscH was rapid,
within 3 min, Fig. 5. Analysis of the plot of absorbance at 265 nm
vs. time, assuming a pseudo ﬁrst-order reaction (in DTT) and ﬁt-
ting to a single exponential, yields a pseudo ﬁrst-order rate
Fig. 3. The direct assay using an Implen Nanophotometer agrees well with results
from the ﬂuorescence plate reader assay. Using the [AscH] from the ﬂuorescence
plate ready assay [15] adjusted for protein precipitation [28] and the [AscH] from
the direct UV/Vis Implen Nanophotometer assay, 179 different samples from sub-
jects were analyzed for AscH . For each sample, the blank used was the plasma
from a blood sample drawn just before infusion of pharmacological AscH in a
treatment session [4–6]. The linear regression that is set to go through the origin
yields a slope of 1.0070.01 and R2¼0.78.
Fig. 4. Ascorbate concentrations determined with “post-infusion – average blank”
vs. “post-infusion – pre-infusion” with differences plotted as residual. Using the
absorbance at 265 nm, 169 samples were analyzed for the concentration of AscH .
For the values of the abscissa the blank was the corresponding plasma of each
subject taken prior to infusion, i.e. pre-infusion, of pharmacological AscH . For the
ordinate the blank was the average of the absorbance at 265 nm (0.2370.04), path
length¼4.00103 cm, of the pre-infusion samples for all 169 subjects. The upper
plot shows the residuals (ordinate value – abscissa value) between the two mea-
surements. The slope of 0.9670.01 demonstrates the ability to estimate supra-
physiological AscH concentrations even if a pre-infusion plasma sample is not
available.
Fig. 5. The reduction of dehydroascorbate to ascorbate by dithiothreitol is rapid.
Dehydroascorbic acid (DHA; 86 mM) in Chelex
s
-treated phosphate buffer (10 mM,
pH 6.5) was dispensed into a 1.00 cm path length cuvette and the UV–vis absor-
bance was monitored using an Implen Nanophotometer P-330. The Nanophot-
ometer was blanked with a 10 mM phosphate buffer, pH 6.5. The solid line with an
absorbance near 0.0 AU at 265 nm is the spectrum for 86 mMDHA. Upon addition of
3200 mM dithiothreitol (DTT) the spectra show the time-dependent increase in the
concentration of AscH due to the reduction of DHA by DTT to AscH . (Inset) The
plot shows the change in the absorbance at 265 nm vs. time. Assuming a pseudo
ﬁrst-order reaction (in DTT) and ﬁtting to a single exponential a pseudo ﬁrst-order
rate constant yields k′¼(3.070.01)102 s1, and k¼9.4 M1 s1 as a second-
order rate constant for the reaction DHAþDTT- AscHþDTToxidized under these
experimental conditions (n¼3).
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order rate constant for the reaction DHAþDTT -
AscHþDTToxidized under these experimental conditions. This is
consistent with the observed rate constant kobs¼0.3 M1 s1 at
pH 7.4 for the reaction of glutathione with DHA, as determined
from the data presented in [32].
When we added DTT to plasma samples, such as those of Fig. 5,
and took an absorbance reading 10 min later, no changes in ab-
sorbances were observed, other than dilution, indicating our
sample handling protocols resulted in no signiﬁcant oxidation of
AscH .
3.6. Ascorbate speciﬁcity
As many biological compounds absorb light in the UV, a simple
approach to conﬁrm that AscH is the analyte being detected at
265 nm is to collect the spectrum ranging from around 200 nm to
at least 350 nm. The peak absorbance of AscH at 265 nm will be
the peak of the spectrum; it should not be on the shoulder of the
absorption spectrum; the absorbance should begin around 230 nm
and end around 300 nm, Fig. 2A. Because the concentration of
AscH can be on the order of 20 mM, the only interference ex-
pected would be from a xenobiotic, not from endogenous proteins
or other natural components of plasma.
3.7. Easy clinical implementation
This technique can be easily implemented in a clinical setting.
The spectrophotometer used here has a small footprint,
E25 cmE50 cm, does not require an external computer, and
can independently print data as a record. The protocol is
J.R. Witmer et al. / Redox Biology 8 (2016) 298–304 303straightforward and requires only to blank the instrument with
water as preparation when subtracting with the average plasma
background, Fig. 4. The absorbance of the plasma can be read di-
rectly with minimal training; no dilutions, and no buffers make it
possible to obtain data within a minute and immediately de-
termine [AscH] to make rapid clinical decisions.4. Conclusions
Here we demonstrate:
1. A microvolume UV/Vis spectrometer can be used to determine
supra-physiological levels of AscH in blood plasma directly
(2.9 mM, lower limit of detection, to at least 35 mM), i.e. with-
out the need for any sample processing;
2. With appropriate sample handling, oxidation of AscH to DHA
in the plasma is not a concern;
3. The effective molar extinction coefﬁcient for the AscH mono-
anion in the matrix of blood plasma appears to be
ε265¼13,000 M1 cm1.
4. An average blank absorbance of 0.23 (4.00103 cm path
length) at 265 nm can be used to determine the [AscH] in
plasma using a microvolume UV/Vis spectrometer;
5. For an optical path length of 4.00103 cm (250 dilution lid
of an Implen Nanophotometer P-330) the concentration of
AscH in plasma (no dilution or processing) can be found using
Eq. (1) when no pre-infusion sample is available, or using Eq. (2)
when a pre-infusion sample is available:
[ ] = ( – )
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( × × ) ( )
−
− − −
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265 265
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These equations can be adjusted for other path lengths; the
blank of Eq. (1) will need to be scaled appropriately. Here the
goal was to assay for AscH in plasma without employing any
chemistries or dilutions. This basic assay can be employed upon
dilution of the plasma sample to accommodate a standard
1.00 cm path length cuvette; attention must then be given to
all aspects of the determination and the analysis.
6. Although the determination of the absorbance of a plasma
sample at 265 nm has good precision, the resulting un-
certainties in the concentration of AscH in plasma have a
coefﬁcient of variation E13% if a pre-infusion sample is avail-
able to be use for the blank. If an average blank is used, then the
coefﬁcient of variation is E20%, because of the biological var-
iation in the absorbance of plasma.Acknowledgments
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